Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via Kvβ1.1 (AKR6A8) subunit of voltage-gated potassium channel

[1]  J. Cuevas,et al.  Kvβ1.1 (AKR6A8) senses pyridine nucleotide changes in the mouse heart and modulates cardiac electrical activity. , 2017, American journal of physiology. Heart and circulatory physiology.

[2]  A. Bhatnagar,et al.  Deletion of Kvβ1.1 subunit leads to electrical and haemodynamic changes causing cardiac hypertrophy in female murine hearts , 2016, Experimental physiology.

[3]  Stefan R Bornstein,et al.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[4]  Jin Han,et al.  Influence of starvation on heart contractility and corticosterone level in rats , 2015, Pflügers Archiv - European Journal of Physiology.

[5]  S. Tipparaju,et al.  High level of oxygen treatment causes cardiotoxicity with arrhythmias and redox modulation. , 2015, Toxicology and applied pharmacology.

[6]  M. Quick,et al.  Potentiation of the Kv1 family K(+) channel by cortisone analogues. , 2012, ACS chemical biology.

[7]  Martina Sauert,et al.  Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. , 2010, Journal of molecular and cellular cardiology.

[8]  O. Pongs,et al.  Ancillary subunits associated with voltage-dependent K+ channels. , 2010, Physiological reviews.

[9]  M. Breschi,et al.  Anti‐ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non‐diabetic rat hearts , 2010, The Journal of pharmacy and pharmacology.

[10]  D. Mukherjee,et al.  Excess of Glucocorticoid Induces Cardiac Dysfunction via Activating Angiotensin II Pathway , 2009, Cellular Physiology and Biochemistry.

[11]  V. Kabaleeswaran,et al.  Cortisone dissociates the Shaker family K+ channels from their beta subunits. , 2008, Nature Chemical Biology.

[12]  A. Bhatnagar,et al.  Catalytic mechanism and substrate specificity of the beta-subunit of the voltage-gated potassium channel. , 2008, Biochemistry.

[13]  M. A. Ramirez,et al.  Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy , 2008, Pharmacotherapy.

[14]  A. Bhatnagar,et al.  NADPH binding to beta-subunit regulates inactivation of voltage-gated K(+) channels. , 2007, Biochemical and biophysical research communications.

[15]  R. Kumar,et al.  Differential regulation of voltage-gated K+ channels by oxidized and reduced pyridine nucleotide coenzymes. , 2005, American journal of physiology. Cell physiology.

[16]  N. Narayanan,et al.  Dexamethasone treatment improves sarcoplasmic reticulum function and contractile performance in aged myocardium , 2004, Molecular and Cellular Biochemistry.

[17]  Brian F. Johnson,et al.  Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. , 2004, Diabetes care.

[18]  A. Zacarias,et al.  Binding of Pyridine Nucleotide Coenzymes to the β-Subunit of the Voltage-sensitive K+ Channel* , 2001, The Journal of Biological Chemistry.

[19]  J. Starkopf,et al.  Pretreatment with methylprednisolone protects the isolated rat heart against ischaemic and oxidative damage , 2000, Free radical research.

[20]  J. Hancox,et al.  An investigation of the role played by the E-4031-sensitive (rapid delayed rectifier) potassium current in isolated rabbit atrioventricular nodal and ventricular myocytes , 1999, Pflügers Archiv.

[21]  N. Hotta,et al.  Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.